Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
0.08Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: 0.78%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.Company Guidance
In the recent Cellectis earnings call for fiscal year 2024, the company provided guidance on several key metrics. Cellectis announced that its cash runway is now extended to mid-2027, thanks to an additional equity investment of $140 million from AstraZeneca, which now owns approximately 44% of Cellectis' share capital and 30% of voting rights. The company also reported that it received $47 million under its collaboration with AstraZeneca, including $25 million upfront and $22 million from development milestones. Cellectis' cash, cash equivalents, and financial assets increased to $264 million as of December 31, 2024, compared to $156 million in the previous year. This increase is attributed to the equity investment, $20 million from the European Investment Bank credit facility, and revenue from partnerships, offset by operational expenses. The company expects to present Phase 1 data for UCART22 and UCART20x22 in 2025 and continues to advance its core clinical trials and collaboration with AstraZeneca.Strategic Collaboration with AstraZeneca
Cellectis announced the start of three research and development programs under its collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca also completed an additional equity investment of $140 million in Cellectis.
Financial Stability and Cash Runway
Cellectis drew down the last tranches of a €40 million credit facility with the European Investment Bank and reported that their cash runway allows operations to be funded into mid-2027. As of December 31, 2024, the company had $264 million in cash, cash equivalents, and fixed term deposits, up from $156 million the previous year.
FDA and European Commission Designations
The FDA granted Orphan Drug Designation and Rare Pediatric Disease status to UCART22, and the European Commission granted Orphan Drug Designation for the treatment of relapse or refractory acute lymphoblastic leukemia.
Advancements in Clinical Trials
Cellectis expects to present Phase 1 data for UCART22 and UCART20x22 in 2025, with plans to open Phase 2 studies in Q4 2025. Recruitment for the BALLI-01 study evaluating UCART22 has progressed well.
Positive Financial Performance
Thanks to the AstraZeneca collaboration, $47 million were received up to year-end 2024, including $22 million from development milestones.
Promising Innovation in CAR T Strategies
Cellectis showcased promising CAR T strategies utilizing TALEN gene editing technology, with preclinical data presented at major conferences and publications in scientific journals.
---
CLLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $1.29 | $1.24 | -3.88% |
| Nov 04, 2024 | $1.76 | $1.78 | +1.14% |
| Aug 06, 2024 | $2.07 | $2.06 | -0.48% |
| May 28, 2024 | $2.78 | $2.72 | -2.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cellectis SA (CLLS) report earnings?
Cellectis SA (CLLS) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cellectis SA (CLLS) earnings time?
Cellectis SA (CLLS) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLLS EPS forecast?
CLLS EPS forecast for the fiscal quarter 2025 (Q1) is -0.15.
---